Ren‐Wang Peng

3.0k total citations
75 papers, 2.2k citations indexed

About

Ren‐Wang Peng is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ren‐Wang Peng has authored 75 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 37 papers in Pulmonary and Respiratory Medicine and 27 papers in Oncology. Recurrent topics in Ren‐Wang Peng's work include Occupational and environmental lung diseases (17 papers), Epigenetics and DNA Methylation (11 papers) and Cellular transport and secretion (11 papers). Ren‐Wang Peng is often cited by papers focused on Occupational and environmental lung diseases (17 papers), Epigenetics and DNA Methylation (11 papers) and Cellular transport and secretion (11 papers). Ren‐Wang Peng collaborates with scholars based in Switzerland, China and Germany. Ren‐Wang Peng's co-authors include Martin Fussenegger, Dieter Gallwitz, Ralph A. Schmid, Haifeng Ye, Marie Daoud‐El Baba, Haitang Yang, Thomas M. Marti, Shun‐Qing Liang, Patrick Dorn and Anna De Antoni and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Ren‐Wang Peng

69 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ren‐Wang Peng Switzerland 29 1.3k 537 506 481 269 75 2.2k
Kiyoko Yoshioka Japan 23 1.6k 1.2× 313 0.6× 693 1.4× 626 1.3× 339 1.3× 38 2.4k
Hira Lal Goel United States 29 2.4k 1.8× 551 1.0× 1.1k 2.2× 632 1.3× 855 3.2× 54 3.6k
Amyn A. Habib United States 32 1.7k 1.3× 502 0.9× 831 1.6× 229 0.5× 667 2.5× 56 3.1k
Olga V. Razorenova United States 25 1.9k 1.5× 256 0.5× 767 1.5× 348 0.7× 737 2.7× 41 3.1k
Ana C. deCarvalho United States 25 1.1k 0.9× 254 0.5× 456 0.9× 199 0.4× 698 2.6× 44 2.0k
W. Nathaniel Brennen United States 23 948 0.7× 404 0.8× 908 1.8× 123 0.3× 505 1.9× 49 2.1k
Karlyne M. Reilly United States 24 913 0.7× 451 0.8× 391 0.8× 182 0.4× 194 0.7× 57 2.3k
Zhenhe Suo Norway 32 1.8k 1.4× 447 0.8× 1.3k 2.5× 290 0.6× 872 3.2× 107 3.1k
Konstantin Stoletov United States 22 1.3k 1.0× 171 0.3× 578 1.1× 836 1.7× 502 1.9× 37 2.3k
Qunsheng Ji China 25 1.5k 1.1× 538 1.0× 686 1.4× 224 0.5× 560 2.1× 50 2.5k

Countries citing papers authored by Ren‐Wang Peng

Since Specialization
Citations

This map shows the geographic impact of Ren‐Wang Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ren‐Wang Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ren‐Wang Peng more than expected).

Fields of papers citing papers by Ren‐Wang Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ren‐Wang Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ren‐Wang Peng. The network helps show where Ren‐Wang Peng may publish in the future.

Co-authorship network of co-authors of Ren‐Wang Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Ren‐Wang Peng. A scholar is included among the top collaborators of Ren‐Wang Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ren‐Wang Peng. Ren‐Wang Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xu, Duo, Yanyun Gao, Tong Hu, et al.. (2025). De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma. EMBO Molecular Medicine. 17(9). 2258–2298.
2.
Lin, Ya‐Wen, Christelle Dubey, Jean‐Louis Reymond, et al.. (2025). Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma. Oncogenesis. 14(1). 28–28.
3.
Tang, Jinming, Min Su, Yuhang Xiao, et al.. (2025). The role of LncRNA SNHG3 in human cancers. Discover Oncology. 16(1). 1812–1812.
4.
Zhao, Liang, Jingyi Zhang, Nicola Zamboni, et al.. (2024). Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer. Cell Death and Differentiation. 32(4). 632–645. 10 indexed citations
5.
Gao, Yanyun, Fabian Blank, Michaela Medová, et al.. (2024). Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism. Cancer Letters. 611. 217353–217353. 4 indexed citations
6.
Yang, Haitang, Yanyun Gao, Duo Xu, et al.. (2023). MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell Death Discovery. 9(1). 55–55. 8 indexed citations
7.
Gao, Yanyun, et al.. (2022). Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma. International Journal of Molecular Sciences. 23(19). 11949–11949. 5 indexed citations
8.
Xu, Duo, Xi Wu, Thomas M. Marti, et al.. (2022). Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses. Cancers. 14(20). 4997–4997. 7 indexed citations
9.
Yang, Haitang, Sean R. R. Hall, Beibei Sun, et al.. (2021). NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers. 13(7). 1561–1561. 28 indexed citations
10.
Zhang, Yang, Shun‐Qing Liang, Haitang Yang, et al.. (2021). CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1 -Amplified Lung Cancer. Cancer Research. 81(11). 3121–3133. 22 indexed citations
11.
Yang, Haitang, Liang Zhao, Yanyun Gao, et al.. (2020). Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. Cancers. 12(11). 3273–3273. 36 indexed citations
12.
Yang, Haitang, Feng Yao, Thomas M. Marti, Ralph A. Schmid, & Ren‐Wang Peng. (2020). Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. Cancers. 12(11). 3389–3389. 29 indexed citations
13.
Yang, Haitang, Duo Xu, Yang Zhang, et al.. (2020). Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers. 12(8). 2310–2310. 14 indexed citations
14.
Xu, Duo, Haitang Yang, Yang Zhang, et al.. (2019). Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma. Cancers. 11(10). 1502–1502. 29 indexed citations
15.
Gao, Yanyun, Patrick Dorn, Sean R. R. Hall, et al.. (2019). Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment. Cancer Cell International. 19(1). 317–317. 30 indexed citations
16.
Xu, Duo, Shun‐Qing Liang, Haitang Yang, et al.. (2019). CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma. Molecular Cancer Therapeutics. 19(2). 661–672. 31 indexed citations
17.
Gao, Yanyun, Nina Hobi, Sabina Berezowska, et al.. (2018). Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. Neoplasia. 21(2). 185–196. 46 indexed citations
18.
Liang, Shun‐Qing, Sabina Berezowska, Thomas M. Marti, et al.. (2018). mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene. 38(5). 622–636. 45 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kiyoko Yoshioka Breakdown of academic impact, for papers by Hira Lal Goel Breakdown of academic impact, for papers by Amyn A. Habib Breakdown of academic impact, for papers by Olga V. Razorenova Breakdown of academic impact, for papers by Ana C. deCarvalho Breakdown of academic impact, for papers by W. Nathaniel Brennen Breakdown of academic impact, for papers by Karlyne M. Reilly Breakdown of academic impact, for papers by Zhenhe Suo Breakdown of academic impact, for papers by Konstantin Stoletov Breakdown of academic impact, for papers by Qunsheng Ji
Rankless by CCL
2026